On January 8, Yasheng Pharmaceutical announced an agreement with partner UNITY Biotechnology (Nasdaq: UBX).UNITY selects a research compound from Yasheng Pharmaceutical as its main development candidate for its ophthalmic product line, and will further conduct preclinical research to advance IND applications.Previously, the two sides have reached a cooperation agreement on the compound library. UNITY is authorized to screen Yasheng Pharmaceutical's Bcl-2 series of compounds for development in the field of anti-aging.At present, both parties have signed a licensing agreement on the selected compound UBX 1967.Under the terms of the license agreement, Yasheng Pharmaceutical has the right to receive advance payments in the form of UNITY common shares, as well as milestone payments and sales share in accordance with UBX 1967 clinical development and commercial sales progress.
"I am glad that UNITY has selected our compound for new drug research in aging-related eye diseases," said Dr. Yang Dajun, chairman of Yasheng Pharmaceutical. "This initiative is also a further affirmation of us, that is, Yasheng Pharmaceutical's leading position in the field of research and development of difficult-to-target protein-protein interaction small molecule inhibitors, including Bcl-2 targets."
About Yasheng Pharmaceutical
Yasheng Pharmaceutical is a China-based, global-oriented, original and innovative drug research and development company dedicated to the development of innovative drugs in therapeutic areas such as cancer, hepatitis B, and aging-related diseases.The company has a self-developed protein-protein interaction targeted drug design platform.Yasheng Pharmaceutical's R & D product pipeline focuses on inhibitors of key proteins in the apoptosis pathway, restarting the apoptosis program of tumor cells by inhibiting BCL-2, IAP, or MDM2-p53, and second- and third-generation inhibitors of kinase mutants that appear in cancer therapy.The company's existing 8 new drug projects have entered Phase I-II clinical development in China, the United States and Australia.
About UNITY Biotechnology
UNITY Biotechnology is committed to extending the healthy lifespan of humans by delaying, terminating or even reversing diseases related to aging.UNITY's research focuses on the development of anti-aging therapeutics based on the removal of senescent cells.By eliminating senescent cells, aging-related diseases such as osteoarthritis, eye diseases, and lung diseases can be treated.